Description:

In April 2018, after a rigorous preregistered clinical trial that was published in the journal Nature Digital Medicine, the U.S. Food and Drug Administration (FDA) de novo authorized IDx-DR® the first autonomous AI system.  IDx-DR diagnoses (DR) and macular edema in adults who have diabetes and identifies those who need to be referred to eye care.   Two years later in November 2020, EyeArt® was 510k cleared by the FDA to market a similar device.  Based on claims data across all insured, only 15.3% of diabetic patients are receiving annual eye exams.  To tackle this gap in care, healthcare providers are implementing point-of-care tests utilizing autonomous AI technology to complete these diabetic retinal exams outside traditional eyecare settings.  This continuing education will not only reveal how AI technology is changing the way DR and macular edema are identified, but it will also help optometrists prepare for this rapidly evolving healthcare delivery model.

Course Code:

AOA223-PB

Speaker(s):

Dana Weitzman, O.D.
dena.weitzman@gmail.com

Credits:

1

AOA Expiration Date:

3/3/2025

Related News

Ask the Coding Experts

You ask, the experts answer. The AOA Coding and Reimbursement Committee supports the AOA's strategic direction to develop and value procedural (CPT), diagnostic (ICD-10) and supply codes (HCPCS). Members can submit questions regarding medical records and coding to askthecodingexpert@aoa.org. Here are the latest questions.

AOA on Capitol Hill 2025: Live News Updates

Welcome to the official news hub for AOA on Capitol Hill 2025! Follow along with the AOA's exclusive coverage from optometry's single-largest federal advocacy event in Washington, D.C., and learn about the issues 600 of our colleagues championed on Capitol Hill.